Advertisement
Screener

VISTAGEN THERAPEUTICS, INC. (VTGN) Deferred Costs

2.8 / 5 stars · 68/120 Roast Me

VISTAGEN THERAPEUTICS, INC. Deferred Costs

VISTAGEN THERAPEUTICS, INC. (VTGN) had Deferred Costs of $334.30 thousand as of 2021-06-30, per its 10-Q filed 2021-08-12.

Discontinued › Balance Sheet › Assets

us-gaap:DeferredCostsCurrentAndNoncurrent · last filed 2021-08-12

  • 2021-06-30: Deferred Costs $334.30K.
  • 2021-03-31: Deferred Costs $367.60K.
  • 2020-12-31: Deferred Costs $409.10K.
  • 2020-09-30: Deferred Costs $438.60K.
Period endDeferred Costs
2021-06-30$334.30K
10-Q · filed 2021-08-12
2021-03-31$367.60K
10-Q · filed 2021-08-12
2020-12-31$409.10K
10-Q · filed 2021-02-11
2020-09-30$438.60K
10-Q · filed 2020-11-12
2020-03-31$0.00
10-Q · filed 2021-02-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
MUSTANG BIO, INC. (MBIO)United States$0.013B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
BIOVIE INC. (BIVI)United States$0.012B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B